NUVATION BIO INC (NUVB)
US67080N1019 - Common Stock
We assign a fundamental rating of 3 out of 10 to NUVB. NUVB was compared to 197 industry peers in the Pharmaceuticals industry. While NUVB has a great health rating, there are worries on its profitability. NUVB is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year NUVB has reported negative net income.
NUVB had a negative operating cash flow in the past year.
In the past 5 years NUVB always reported negative net income.
In the past 5 years NUVB always reported negative operating cash flow.
1.2 Ratios
With a decent Return On Assets value of -12.20%, NUVB is doing good in the industry, outperforming 71.28% of the companies in the same industry.
With a decent Return On Equity value of -12.53%, NUVB is doing good in the industry, outperforming 78.97% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -12.2% | ||
| ROE | -12.53% | ||
| ROIC | N/A |
ROA(3y)-12.96%
ROA(5y)-19.12%
ROE(3y)-13.36%
ROE(5y)-19.69%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for NUVB so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
NUVB has more shares outstanding than it did 1 year ago.
NUVB has more shares outstanding than it did 5 years ago.
There is no outstanding debt for NUVB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
NUVB has an Altman-Z score of 29.89. This indicates that NUVB is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of NUVB (29.89) is better than 94.87% of its industry peers.
There is no outstanding debt for NUVB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 29.89 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
NUVB has a Current Ratio of 44.11. This indicates that NUVB is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 44.11, NUVB belongs to the best of the industry, outperforming 98.97% of the companies in the same industry.
NUVB has a Quick Ratio of 44.11. This indicates that NUVB is financially healthy and has no problem in meeting its short term obligations.
NUVB's Quick ratio of 44.11 is amongst the best of the industry. NUVB outperforms 98.97% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 44.11 | ||
| Quick Ratio | 44.11 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 29.17% over the past year.
EPS 1Y (TTM)29.17%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q40%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A
3.2 Future
The Earnings Per Share is expected to decrease by -5.71% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-11.66%
EPS Next 2Y-27.57%
EPS Next 3Y-27.14%
EPS Next 5Y-5.71%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for NUVB. In the last year negative earnings were reported.
Also next year NUVB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as NUVB's earnings are expected to decrease with -27.14% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-27.57%
EPS Next 3Y-27.14%
5. Dividend
5.1 Amount
No dividends for NUVB!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NUVATION BIO INC
NYSE:NUVB (5/17/2024, 7:16:56 PM)
After market: 3.32 0 (0%)3.32
-0.09 (-2.64%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap819.01M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -12.2% | ||
| ROE | -12.53% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 44.11 | ||
| Quick Ratio | 44.11 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)29.17%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-11.66%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y